A Pilot Study Suggests that the G/G Genotype of Resistin Single Nucleotide Polymorphism at -420 May Be an Independent Predictor of a Reduction in Fasting Plasma Glucose and Insulin Resistance by Pioglitazone in Type 2 Diabetes

Endocrine Journal

Hideichi MAKINO⁹  Hiroshi ONUMA²  Shiori KONDO⁵  Jun OHASHI⁶  Wataru NISHIDA²  Yasuharu TAKADA⁷  Kenichi IZUMI⁵  Satoshi MURAO⁸  Junko YAMAUCHI²  Yasunori TAKATA²  Ryoichi KAWAMURA²  Yasuhisa FUJII⁹  Kazuaki NAKAI^2,10  Haruhiko OSAWA²  Masao FUJIYAMA¹  Ikki SHIMIZU⁴  Mitsuru HASHIRAMOTO²  Yasuharu TABARA³ 

[1] Fujiyama Clinic, Ehime, Japan;Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan;Department of Basic Medical Research and Education,Ehime University Graduate School of Medicine, Ehime, Japan;Ehime Prefectural Central Hospital, Ehime, Japan;Matsuyama Red Cross Hospital, Ehime, Japan;Doctoral Program in Life System Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan;Saijo Central Hospital, Ehime, Japan;Matsuyama-Shimin Hospital, Ehime, Japan;Institute of Diabetes Research Center, Takanoko Hospital, Ehime, Japan;Ehime Rosai Hospital, Ehime, Japan

关键词: Pioglitazone;    Resistin;    SNP;    Insulin resistance;    Type 2 diabetes;   

DOI  :  10.1507/endocrj.K08E-320

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(41)Cited-By(11)The aim of this study was to determine the relation between the G/G genotype of a resistin gene promoter single nucleotide polymorphism (SNP) at -420 (rs1862513) and glycemic control by pioglitazone in type 2 diabetes. In Study 1, 121 type 2 diabetic patients were treated with pioglitazone (15 or 30 mg/day) for 12 weeks, in addition to previous medication. In Study 2, 63 patients who had been treated with pioglitazone for 12 weeks were examined retrospectively. In Study 1, multiple regression analysis revealed that the G/G but not C/G genotype was correlated with a reduction in fasting plasma glucose (FPG) and homeostasis model assessment of insulin resistance (HOMA-IR) compared to C/C. When adjusted for age, gender, and BMI, the G/G genotype was an independent factor for the reduction of FPG (P=0.020) and HOMA-IR (P =0.012). When studies 1 and 2 were combined by adjusting the studies, age, gender, and BMI, the reduction of HbA1c was correlated with the G/G genotype (β=-0.511, P=0.044). Therefore, this pilot study suggests that the G/G genotype of resistin SNP –420 may be an independent predictor of the reduction of fasting plasma glucose and HOMA-IR by pioglitazone.

【 授权许可】

Unknown